Across TCGA pan-cancer cohorts, ARHGEF15 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARHGEF15 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARHGEF15 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF15 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SCLC, and BRCA are the cancer types where ARHGEF15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.923	0.613	.006	16	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
BRCA	DFS	Median	II,III,IV	0.315	0.889	.007	12	view →
SARC	DFS	Median	All	0.069	0.632	<.001	12	view →
LUAD	OS	Median	All	0.321	0.702	.007	6	view →
SKCM	OS	Median	III,IV	0.353	0.729	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: ARHGEF15 tumor-vs-normal RNA expression · all ARHGEF15 data types